Unbound Cloxacillin Concentrations During Continuous Infusion
NCT ID: NCT06848387
Last Updated: 2025-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
25 participants
INTERVENTIONAL
2025-12-31
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
NCT06726395
Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia
NCT06495697
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
NCT01792804
Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion
NCT00435305
Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.
NCT01875263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
1. Cloxacillin is used in accordance with the terms of the marketing authorization
2. The use of cloxacillin is evidence-based
3. The additional monitoring procedures - four blood samples drawn before, after 4h, after 24h, and after 48h of continuous infusion of cloxacillin - do not pose more than minimal additional risk or burden to the safety of the subjects compared to normal clinical practice.
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with cloxacillin as continuous infusion via elastomeric pump
Additional monitoring procedures performed: blood samples drawn before, after 4h, after 24h, and after 48h of continuous infusion of cloxacillin.
Unbound cloxacillin concentration
Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Unbound cloxacillin concentration
Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treating physician has decided to start continuous infusion of cloxacillin
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Västmanland
OTHER
Emeli Månsson
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emeli Månsson
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Karl-Johan Lindner, PhD
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
992496/KLONC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.